Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037246 | 1.00 | CYP1A2 (0.42) | CYP1A2CYP2D6PTPN1CYP2C19CYP3A4 | |
| SCHEMBL9282288 | 0.79 | CYP3A4 (0.33) | CYP2C19CYP3A4CYP2C9NPSR1SMN1; SMN2 | |
| SCHEMBL2089215 | 0.75 | CYP1A2 (0.52) | CYP1A2CYP2D6CYP2C19KMT2AHIF1A | |
| SCHEMBL28991134 | 0.74 | CYP1A2 (0.46) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL7363683 | 0.69 | KMT2A (0.40) | CYP2C19CYP3A4CYP2C9NPSR1MEN1 | |
| SCHEMBL9282285 | 0.68 | KIF11 (0.33) | CYP1A2CYP2D6PTPN1CYP2C19CYP3A4 | |
| SCHEMBL10881374 | 0.68 | PTPN1 (0.47) | PTPN1NPSR1MEN1KMT2AHTT | |
| SCHEMBL6037244 | 0.67 | MEN1 (0.41) | CYP1A2CYP2D6PTPN1CYP2C19CYP3A4 | |
| SCHEMBL5689660 | 0.65 | CYP1A2 (0.37) | CYP1A2CYP2D6NPSR1LMNA | |
| SCHEMBL15239188 | 0.64 | PTPN1 (0.52) | CYP1A2CYP2D6PTPN1CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060088877-A1 | Systematic evolution of ligands by exponential enrichment: Chemi-SELEX | GILEAD SCIENCES, INC. (US) | 2006-04-27 | — | — | US | disclosed |
| EP-0840742-A4 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: CHEMI-SELEX | NEXSTAR PHARMACEUTICALS INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20030186231-A1 | Systematic evolution of ligands by exponential enrichment: Chemi-ESLEX | GILEAD SCIENCES, INC. | 2003-10-02 | — | — | US | disclosed |
| US-6300074-B1 | A NUCLEIC ACID LIGAND CONTAINING A CHEMICALLY REACTIVE FUNCTIONAL GROUP BOND TO A TARGET LIGAND FORMING A COVALENT COMPLEX FOR EFFECIENT PARTIONING OF THE DESIRED COMPLEX IN A CANDIDATE MIXTURE | GILEAD SCIENCES, INC. | 2001-10-09 | — | — | US | disclosed |
| US-5998142-A | NUCLEIC ACID LIGAND WHICH BINDS TO PROTEIN | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5962219-A | DETECTING NUCLEIC ACIDS WITH ACTIVITY BY MIXING WITH TARGET, FORMING COVALENT BOND BETWEEN TARGET AND CHEMICALLY REACTIVE UNIT OF NUCLEIC ACID, SEPARATING NUCLEIC ACIDS WITH ACTIVITY FROM NONREACTIVE NUCLEIC ACIDS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5763595-A | NUCLEIC ACID LIGANDS WHICH BIND COVALENTLY WITH PROTEIN | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0840742-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: CHEMI-SELEX | NeXstar Pharmaceuticals, Inc. (US) | 1998-05-13 | — | — | EP | disclosed |
| US-5705337-A | NUCLEIC ACID DETECTION OF LIGANDS THAT BIND COVALENTLY WITH TARGET MOLECULE COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1996027605-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: CHEMI-SELEX | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088877-A1 | Systematic evolution of ligands by exponential enrichment: Chemi-SELEX | CLASP1, PCNA, DCLRE1B | CYP1A2 4546/4885CYP2D6 4237/4885PTPN1 4682/4885 |
| US-20030186231-A1 | Systematic evolution of ligands by exponential enrichment: Chemi-ESLEX | CLASP1, DCLRE1B, PCNA | CYP1A2 4813/4885CYP2D6 4521/4885PTPN1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.